Top News - 500 Beiträge pro Seite

[kafutznik]

http://www.stockhouse.ca/news/news.asp?tick=PRAI&newsid=2911…

[yoppu]

Wieder ein Schritt in die richtige Richtung!
Mal sehen wieviel Prozent das den Amis heute wert ist!?

[kafutznik]

Ich denke mal das es gut hoch gehen wird wir werden sehen ist auf jeden fall ne gute Nachricht mal schauen was Vorbörslich passiert

[Baby1001]

Wenn das mal nicht ein Anstoß ist damit die Aktie gen Norden geht

Biomira announces PRA International to assist with completion of BLP25 Liposome Vaccine Phase 3 study in non-small cell lung cancer
Monday September 12, 6:00 am ET


EDMONTON, Sept. 12 /CNW/ - Biomira Inc. (Nasdaq:BIOM - News; TSX:BRA - News), a leading developer of cancer vaccines, today announced the engagement of PRA International, a leading global clinical research organization, to assist Biomira and Merck KGaA of Darmstadt, Germany, with the planned phase 3 trial of BLP25 Liposome Vaccine (L-BLP25) for the treatment of non-small cell lung cancer. The study is expected to commence towards the end of 2005. The trial design is currently being discussed with the FDA.
ADVERTISEMENT


Guy Ely, M.D., Vice President Clinical and Medical Affairs of Biomira commented, " We are pleased to announce this relationship as it signifies an important step in advancing L-BLP25. Our phase 2b data were very compelling and we look forward to working with PRA as we work towards beginning our phase 3 trial by the end of the year."

PRA International is one of the world`s leading global clinical development organizations, with over 2,500 employees in North America, Europe, South America, Africa, Australia, and Asia. PRA, an ISO 9001:2000 registered company, delivers services to its clients through a unique approach called Project Assurance(SM), which represents PRA`s commitment to reliable service delivery, program-level therapeutic expertise, easy, global access to knowledge, and involved senior management. To learn more about PRA International, please visit http://www.prainternational.com or call their World Headquarters at [phone].

The Companies

Our key collaboration in developing therapeutic cancer vaccines is with Merck KGaA. Merck is a global pharmaceutical and chemical company with sales of EUR 5.9 billion in 2004, a history that began in 1668, and a future shaped by 28,900 employees in 52 countries. Its success is characterized by innovations from entrepreneurial employees. Merck`s operating activities come under the umbrella of Merck KGaA, in which the Merck family holds a 73 per cent interest and free shareholders own the remaining 27 per cent. The former U.S. subsidiary, Merck & Co., has been completely independent of the Merck Group since 1917. Merck KGaA has built a strategic oncology portfolio by developing and in-licensing product candidates in four areas - monoclonal antibodies, therapeutic vaccines, immunocytokines and angiogenesis inhibitors.

EMD Pharmaceuticals Inc., the U.S. affiliate of Merck KGaA, is a fully integrated pharmaceutical company with an initial emphasis on launching new products in oncology. Located in Durham, N.C., EMD focuses on meeting patient and physician needs with pioneering pharmaceutical products and services.

Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. Biomira`s commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy.


This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected in
forward-looking statements, including those predicting the timing and results
of clinical trials, availability or adequacy of financing, the sales and
marketing of commercial products or the efficacy of products. Although the
Company believes that the forward-looking statements contained herein are
reasonable, it can give no assurance that the Company`s expectations are
correct. All forward-looking statements are expressly qualified in their
entirety by this cautionary statement.

For further information

Biomira Company Contact: Bill Wickson, Manager, Public Relations, [phone]
After hours contact: [e-mail]
U.S. Media Contact: Jonathan Birt, Financial Dynamics, [phone], [e-mail]
U.S. Investor Contact: John Capodanno, Financial Dynamics, [phone], [e-mail]
To request a free copy of this organization`s annual report, please go to http://www.newswire.ca and click on reports@cnw.

[yoppu]

wird ja auch Zeit das es wieder über 3$ geht, dass Potential von Biomira ist rießig!

[kafutznik]

Mal sehen wie die Amis gleich darauf reagieren,biotechs laufen momentan sehr gut und die Nachricht ist mehr als gut

[kafutznik]

Jetzt gehts los an den deutschen Börsen

[yoppu]

haja wenn wir hier die Nachricht schon früher bekommen, muss das ja auch genutzt werden!

[kafutznik]

eben ask 1,46

[kafutznik]

ASK 1,50 die Nachricht ist Gold wert

[Baby1001]

Tips wo wir heute Abend stehen werden, wer traut sich?!

[yoppu]

wurden doch schon 1,51 gezahlt!

[kafutznik]

erster kurs ask 1,70 das gibt ein feuerwerk nach dieser nachricht

[yoppu]

mal sehen was die Amis davon halten, bei der letzten Hammermeldung gings von 1,50$ auf 4$ innerhalb von zwei Tagen.

[kafutznik]

jetzt amilamd 1,90

[yoppu]

ich tippe mal auf 3,20$ also ein Verdoppler, schließlich sind Biotechs gerade wieder voll im Trend!

[kafutznik]

Das kann leicht sein ist ja auch ne Toppmeldung und in Amiland stehen sie ja jetzt erst auf

[kafutznik]

ASK in Deutschland 1,55

[yoppu]

maximal noch ne Stunde kann man hier in Deutschland ungestört sammeln! Dann werden sich wohl die Amis um den Preis bemühen!

[kafutznik]

Ask Deutschland 1,60

[kafutznik]

Orderbuch in Amiland sehr Interresan bis 2,61 Dollar kein widerstand

[kafutznik]

ASK + Bid zieht in Canada jetzt auch an

[kafutznik]

Un morgen liegt auch etwas an

Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) announced today that Alex McPherson, MD, PhD, President and CEO of Biomira, will present highlights of the Company`s lead product and corporate plans at the Bear Stearns 18th Annual Healthcare Conference at the Grand Hyatt Hotel, New York, NY. The presentation will be held on Tuesday, September 13, 2005 from 8:00 a.m. until 8:25 a.m. EST.

[kafutznik]

1,64 ask in deutschland

[DausendUndMehr]

[kafutznik]

So jetzt ist es bald soweit mal sehen was Vorbörslich ab geht

[yoppu]

joa man darf gespannt sein!

[kafutznik]

Ami 1,88

[yoppu]

die erstem kleinen Umsätze starten bei 1,90$
Da geht heute noch was!

[DausendUndMehr]

schau mer mal

[schnegg]

9500St. zu 1,51€ übern Tresen

was steht in der News eigentlich drinne´???

[DausendUndMehr]

beruhigt sich schon wieder

Pre-Market Time (ET) Pre-Market Price Pre-Market Share Volume
08.09 $ 1.76 1800
08.06 $ 1.80 500
08.05 $ 1.80 500
08.04 $ 1.75 453
08.04 $ 1.75 1000
08.04 $ 1.75 147
08.04 $ 1.72 853
08.03 $ 1.75 400
08.03 $ 1.72 2000
08.03 $ 1.75 100
08.03 $ 1.75 500
08.03 $ 1.75 1000
08.03 $ 1.75 400
08.01 $ 1.78 1500
08.01 $ 1.78 500
08.01 $ 1.73 300
08.01 $ 1.73 100
08.01 $ 1.88 400
08.01 $ 1.90 200
08.01 $ 1.90 100
08.01 $ 1.88 100
08.01 $ 1.90 100
08.01 $ 1.90 100
08.01 $ 1.88 100
08.01 $ 1.90 100
08.01 $ 1.90 400

[kafutznik]

Geht sowieso erst nach 15 Uhr richtig los

[yoppu]

wie gesagt, vor 14:30-15:00 Uhr kann man noch garnichts an den Realtime Kursen ablesen!
Werden bis dahin eh nur PEanuts gehandelt!

[DausendUndMehr]

1.79

[yoppu]

1,84 wenn schon!

[DausendUndMehr]

jetzt ja

[kafutznik]

Die Taxen wie blöde in Amiland

[peter47]

@All
Ich denke heute wird ein "heißer" Tag
VG Peter

[schnegg]

kann einer die NEWS ÜBERSETZEN????

[DausendUndMehr]

RT 1.75

[kafutznik]

1,77

[DausendUndMehr]

das mit den 3$ wird heute nix

[DausendUndMehr]

jetzt ist die Meldung auch auf der Biomira Homepage zu finden

http://www.biomira.com/news/detailNewsRelease/230/

[yoppu]

naja ein Versuch wars wert!

[schnegg]

ABER DER KNALL WIRD KOMMEN!!!!!!


10.000 zu 10$=100.000$$$$$$$$$$$$$$$$


man muß nur warten können!!!

[BeNeLux]

Bei 1,76 ist/war ein fetter Block , der erst weggekauft werden musste . Der "Weg" ist jetzt einigermassen frei

[DausendUndMehr]

Nasdaq BIOM USD 1,65 1,74 +0,090 +5,46 % 1,23 Mio. 716.735 12. Sep 22:37

[peter47]

[posting]17.871.330 von DausendUndMehr am 12.09.05 22:53:37[/posting]@DausendUndMehr
An und für sich, recht geringer Umsatz gestern.
VG Peter

[kafutznik]

die haben heute eine präsentation ich denke bis dahin halten sich einige zurück mal sehen kann auf jeden fall sehr schnell hochgehen

[wayne99]

Soeben über den Ticker gekommen:

Press Release Source: Biomira Inc.

Biomira announces completion of enrolment in BLP25 Liposome Vaccine phase 2 safety study
Tuesday September 13, 6:00 am ET

EDMONTON, Sept. 13 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM - News; TSX: BRA - News), a leading developer of cancer vaccines, today announced that it has completed the enrolment of a 20-patient phase 2, single-arm, multi-centre, open label study of BLP25 Liposome Vaccine (L-BLP25). The drug is being developed in collaboration with Merck KGaA of Darmstadt, Germany.

ADVERTISEMENT
The phase 2 trial will assess the safety of the formulation of L-BLP25 that the Companies plan to use in the upcoming phase 3 study. The phase 3 trial design is currently being discussed with the FDA. The formulation incorporates manufacturing changes intended to secure the future commercial supply of the vaccine. Initial results from the 20-patient trial involving men and women with non-small cell lung cancer (NSCLC) from eight clinical trial sites in Canada are anticipated before the end of 2005.

"The completion of enrolment for this phase 2 safety study is another important step toward commencing our large, multi-national phase 3 study, which we expect to begin by the end of this year," said Alex McPherson, MD, PhD, President and CEO.

About Lung Cancer

In 2004, approximately 174,000 new cases of lung were diagnosed in the U.S. Approximately 160,000 people are estimated to have died of this disease in the U.S. alone in 2004. NSCLC accounts for approximately 75 to 80 per cent of all primary lung cancers. At the time of diagnosis, only 25 per cent of patients are potentially curable by surgery.

The Companies

Our key collaboration in developing therapeutic cancer vaccines is with Merck KGaA. Merck is a global pharmaceutical and chemical company with sales of EUR 5.9 billion in 2004, a history that began in 1668, and a future shaped by 28,900 employees in 52 countries. Its success is characterized by innovations from entrepreneurial employees. Merck`s operating activities come under the umbrella of Merck KGaA, in which the Merck family holds a 73 per cent interest and free shareholders own the remaining 27 per cent. The former U.S. subsidiary, Merck & Co., has been completely independent of the Merck Group since 1917. Merck KGaA has built a strategic oncology portfolio by developing and in-licensing product candidates in four areas - monoclonal antibodies, therapeutic vaccines, immunocytokines and angiogenesis inhibitors.

EMD Pharmaceuticals Inc., the U.S. affiliate of Merck KGaA, is a fully integrated pharmaceutical company with an initial emphasis on launching new products in oncology. Located in Durham, N.C., EMD focuses on meeting patient and physician needs with pioneering pharmaceutical products and services.

Biomira is a biotechnology company specializing in the development of innovative therapeutic approaches to cancer management. Biomira`s commitment to the treatment of cancer currently focuses on the development of synthetic vaccines and novel strategies for cancer immunotherapy.

This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing, duration and results of clinical trials, trial reviews and analyses and regulatory reviews, or the safety and efficacy of the product. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company`s expectations are correct or that the Company will have sufficient resources to fund clinical trials. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.


Source: Biomira Inc.

[wayne99]

Diese Meldung ist sehr erfreulich für BIOM - da sollte sich heute mehr bewegen als bei der gestrigen PR

[DausendUndMehr]

wie gestern, schaun wir mal in knapp 3 Stunden

[La_Differenza]

Phase 3 wird zurzeit mit der FDA besprochen.

schon Ende Nov ?

[kafutznik]

Da werden sich jetzt viele positionieren echt ne Hammermeldung

[BeNeLux]

Schau mer mal ....

[yoppu]

Da passiert dieses Jahr noch was!
Die Frage ist nur wann die Amis das merken!

[kafutznik]

Jetzt warten alle was Amerika macht und wenns heute schon hoch geht laufen wieder alle hinterher

[yoppu]

Bei Biomira lohnt sich auch ein hinterherlaufen, die Story ist einfach zu gut!

[La_Differenza]

[kafutznik]

Es verkauft keiner

[La_Differenza]

[posting]17.878.482 von kafutznik am 13.09.05 13:59:34[/posting]Es kauft auch keiner

mal schauen wie es vorbörslich drüben aussieht.

[peter47]

[posting]17.878.520 von La_Differenza am 13.09.05 14:01:59[/posting]Doch ich. Aber nur Testen
VG Peter

[DausendUndMehr]

nicht so der Hit was heute (nicht) abgeht ...

[peter47]

[posting]17.881.065 von DausendUndMehr am 13.09.05 16:33:52[/posting]Hit??? Nein da hast du recht: Ich konnte aber noch ein bisserl was günstg bekommen
VG Peter

[peter47]

@All
Ein wenig seltsam, der Handel in USA
VG Peter